Current cancer therapies often fail due to tumor cells' ability to adapt and evade treatment, as well as the immunosuppressive environment surrounding the tumor. Many treatments do not effectively target both the tumor's growth mechanisms and the immune system's response to the cancer.

WM Therapeutics is developing small-molecule cancer therapies designed to simultaneously inhibit tumor growth and enhance the body's immune response. Their approach focuses on disrupting tumor-autonomous growth pathways while also modifying the immune microenvironment to promote anti-tumor immunity. By targeting both aspects of cancer progression, WM Therapeutics aims to provide more effective and durable treatment options. The company's Integrated Stress Response (ISR) platform is used to identify and develop these novel therapies for both cancer and inflammation.

Small-molecule drug candidates targeting tumor-autonomous growth mechanisms

Immunomodulatory agents designed to enhance the anti-tumor immune response

Integrated Stress Response (ISR) platform for drug discovery

Focus on modifying the tumor microenvironment to overcome immunosuppression

The primary target audience includes patients with cancer and inflammatory diseases, as well as oncologists and researchers seeking more effective treatment options.